SYRE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SYRE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
Spyre Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-0.782. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-41.78 for the trailing ten years ended in Mar. 2024.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
As of today (2024-06-06), Spyre Therapeutics's current stock price is $33.80. Spyre Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-41.78. Spyre Therapeutics's Cyclically Adjusted Price-to-FCF of today is .
The historical data trend for Spyre Therapeutics's Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | - | - | - | -41.61 | -41.78 |
For the Biotechnology subindustry, Spyre Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's Cyclically Adjusted Price-to-FCF falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Spyre Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | -0.782 | / | 131.7762 | * | 131.7762 | |
= | -0.782 |
Current CPI (Mar. 2024) = 131.7762.
Spyre Therapeutics Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201406 | -4.458 | 100.560 | -5.842 |
201409 | -6.868 | 100.428 | -9.012 |
201412 | -11.231 | 99.070 | -14.939 |
201503 | -9.132 | 99.621 | -12.080 |
201506 | -14.209 | 100.684 | -18.597 |
201509 | -14.451 | 100.392 | -18.969 |
201512 | -1.910 | 99.792 | -2.522 |
201603 | -8.731 | 100.470 | -11.452 |
201606 | -10.023 | 101.688 | -12.989 |
201609 | -11.004 | 101.861 | -14.236 |
201612 | -8.366 | 101.863 | -10.823 |
201703 | -10.660 | 102.862 | -13.656 |
201706 | -10.598 | 103.349 | -13.513 |
201709 | -11.401 | 104.136 | -14.427 |
201712 | -9.133 | 104.011 | -11.571 |
201803 | -11.289 | 105.290 | -14.129 |
201806 | -11.018 | 106.317 | -13.656 |
201809 | -9.787 | 106.507 | -12.109 |
201812 | -7.719 | 105.998 | -9.596 |
201903 | -13.728 | 107.251 | -16.867 |
201906 | -12.511 | 108.070 | -15.255 |
201909 | -13.185 | 108.329 | -16.039 |
201912 | -13.233 | 108.420 | -16.084 |
202003 | -17.434 | 108.902 | -21.096 |
202006 | -9.791 | 108.767 | -11.862 |
202009 | -7.270 | 109.815 | -8.724 |
202012 | -6.966 | 109.897 | -8.353 |
202103 | -7.614 | 111.754 | -8.978 |
202106 | 0.782 | 114.631 | 0.899 |
202109 | -6.494 | 115.734 | -7.394 |
202112 | -7.304 | 117.630 | -8.182 |
202203 | -9.962 | 121.301 | -10.822 |
202206 | -6.287 | 125.017 | -6.627 |
202209 | -3.999 | 125.227 | -4.208 |
202212 | -4.754 | 125.222 | -5.003 |
202303 | -4.676 | 127.348 | -4.839 |
202306 | -4.353 | 128.729 | -4.456 |
202309 | -8.057 | 129.860 | -8.176 |
202312 | -0.861 | 129.419 | -0.877 |
202403 | -0.782 | 131.776 | -0.782 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.
For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.
Thank you for viewing the detailed overview of Spyre Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott L Burrows | officer: Chief Financial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Heidy King-jones | officer: See Remarks | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Fairmount Healthcare Co-invest L.p. | director, 10 percent owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Peter Evan Harwin | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Fairmount Funds Management Llc | director, 10 percent owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Cameron Turtle | officer: Chief Operating Officer | C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104 |
Michael Thomas Henderson | director | 421 KIPLING STREET, PALO ALTO CA 94301 |
Fairmount Healthcare Fund L.p. | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Fairmount Healthcare Fund Ii L.p. | director, 10 percent owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Tomas Kiselak | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Jeff Marc Goldberg | director, officer: President and CEO | C/O AKCEA THERAPEUTICS, 55 CAMBRIDGE PARKWAY, STE 100, CAMBRIDGE MA 02142 |
Linda L Neuman | officer: Chief Medical Officer | C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746 |
Marcio Souza | director | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
James Paul Kastenmayer | officer: Interim CEO & General Counsel | ONE MEDIMMUNE WAY, FLOOR ONE, AREA TWO, GAITHERSBURG MD 20879 |
Hanley Jr. Michael Conick | officer: Chief Commercial Officer | C/O AEGLEA THERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746 |
From GuruFocus
By PRNewswire PRNewswire • 04-12-2023
By PRNewswire • 06-22-2023
By PRNewswire • 09-14-2023
By PRNewswire PRNewswire • 08-19-2022
By PRNewswire PRNewswire • 12-02-2022
By PRNewswire PRNewswire • 03-02-2023
By PRNewswire PRNewswire • 03-17-2023
By PRNewswire PRNewswire • 08-04-2022
By PRNewswire PRNewswire • 07-02-2022
By PRNewswire PRNewswire • 05-11-2023